Humanin vs Substance P

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Humanin

Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.

Full details →

Substance P

Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.

Full details →

Side-by-Side Comparison

Aspect	Humanin	Substance P
Dose Range	100 mcg–500 mcg	35 mcg–350 mcg
Frequency	1x daily	1x daily
Cycle Length	4–8 weeks	1 weeks
Route	subcutaneous	subcutaneous
Mechanism	Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress.	Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells.
Typical Dosage	Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog.	Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea.
Administration	Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities.	Research compound only. Therapeutic applications focus on blocking rather than administering Substance P.
Side Effects	Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism.	Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically.
Best For	Cognitive Performance Anti-Aging & Longevity	Cognitive Performance